opa1

OPA1 (Optic Atrophy 1)

A large dynamin-related GTPase anchored in the inner mitochondrial membrane (IMM) that performs two mechanistically linked functions central to mitochondrial quality in aging: (1) IMM fusion, working in concert with the OMM-fusion mitofusins, and (2) cristae junction control, where OPA1 oligomers seal the tubular junctions between cristae and the intermembrane space to sequester ~80–85% of the cytochrome-c pool away from the OMM permeabilisation machinery (Frezza 2006: ~15–20% of cytochrome c is IMS-free at baseline). Loss-of-function OPA1 mutations cause autosomal dominant optic atrophy (ADOA), the most common hereditary optic neuropathy. In aging biology, OPA1 reduction in aged and failing cardiac and skeletal muscle mirrors the broader shift toward mitochondrial network fragmentation characteristic of the mitochondrial-dysfunction hallmark.

Identity

• UniProt: O60313 (OPA1_HUMAN) — Swiss-Prot manually reviewed
• NCBI Gene: 4976
• HGNC symbol: OPA1
• Ensembl: ENSG00000198836
• Mouse ortholog: Opa1 (Mus musculus; one-to-one ortholog; high sequence identity)
• Length: 960 amino acids (canonical isoform 1)
• Molecular weight: ~112 kDa (deduced from sequence; apparent MW on SDS-PAGE ~80 kDa for S-OPA1 and ~100 kDa for L-OPA1 forms)
• GenAge: Not listed as of 2026-05-04

Domain architecture

OPA1 is a type I transmembrane protein anchored in the IMM via a single N-terminal transmembrane segment. UniProt O60313 specifies the following structural regions (approximate residues for isoform 1):

Region	Approximate residues	Function
Mitochondrial targeting sequence (MTS)	1–88	Cleaved in transit; directs import through TIM23 complex into the IMM
Transmembrane segment	~89–120	Single-pass IMM anchor; N-terminus in the matrix, bulk of protein in the IMS
Coiled-coil (N-terminal)	~210–254	Self-association; required for oligomerization and cristae junction sealing
GTPase domain	~285–561	Dynamin-family GTP-binding and hydrolysis; G1–G5 motifs; drives membrane curvature and fusion
Middle domain / stalk	~562–740	Mediates higher-order assembly; paddle region (~736–856) with a membrane-insertion loop for lipid interaction
GTPase effector domain (GED)	~874–960	Allosterically contacts GTPase domain; stimulates GTP hydrolysis
Coiled-coil (C-terminal)	~895–960	Coiled-coil at GED C-terminus; contributes to oligomer bundling

This domain layout is homologous to other dynamin-family members (dynamin-1, DRP1, atlastin) but the IMM topology and obligatory transmembrane anchor distinguish OPA1 from the cytosolic GTPases.

Isoform diversity and proteolytic processing — L-OPA1 and S-OPA1

Eight splice isoforms exist in humans, generated by alternative inclusion of exons 4, 4b, and 5b. Isoforms differ in the juxtamembrane region near the transmembrane anchor and thereby differ in their susceptibility to proteolytic cleavage. Isoforms containing exon 4b support mitochondrial genome maintenance (independent of fusion activity). Tissue expression patterns of isoforms vary; the brain expresses a broad range while skeletal muscle and heart show more restricted sets.

All isoforms are proteolytically processed to generate two functional forms that coexist in the IMM:

Long form (L-OPA1)

The transmembrane-anchored, IMM-integral species. L-OPA1 is the product of constitutive cleavage of the MTS and import; it retains the transmembrane segment and therefore remains fixed in the IMM. Under healthy, energized conditions, L-OPA1 predominates. L-OPA1 can form oligomeric assemblies by itself and is the form that, together with S-OPA1, is required for IMM fusion.

Short form (S-OPA1)

Soluble in the intermembrane space (IMS). S-OPA1 arises from two regulated proteolytic cleavages at sites within or near the transmembrane segment:

Protease	Site	Conditions that activate
yme1l (i-AAA protease)	S2 cleavage site	Constitutive under physiological conditions; generates S-OPA1 during routine IMM homeostasis
oma1 (zinc metalloprotease)	S1 cleavage site	Activated by stress: mitochondrial membrane potential (ΔΨm) collapse, proteotoxic stress, heat shock, CCCP treatment; cleaves the entire L-OPA1 pool to S-OPA1

Anand et al. 2014 established that both YME1L and OMA1 together balance fusion and fission by adjusting the L-OPA1/S-OPA1 ratio ¹. Under physiological conditions, both L- and S-OPA1 coexist and both are required for IMM fusion: S-OPA1 alone cannot drive fusion; L-OPA1 alone has reduced activity; the two forms cooperate in cis or trans on the opposing IMMs. Under stress — ΔΨm collapse, as occurs on damaged mitochondria — OMA1 is rapidly activated and converts all L-OPA1 to S-OPA1, completely abolishing IMM fusion capacity on that organelle and enforcing its isolation, a prerequisite for mitophagy clearance.

Dimension	Status
Pathway conserved in humans?	yes — OPA1, OMA1, and YME1L are human genes; mechanism characterised in human cell lines
Phenotype conserved in humans?	yes — OPA1 haploinsufficiency causes human ADOA (dominant optic atrophy)
Replicated in humans?	yes (disease genetics); aging-specific reduction only partially replicated

Function 1 — Inner mitochondrial membrane fusion

OPA1 catalyses fusion of the IMM — the second of two sequential membrane-merger events required to fully join two mitochondria (OMM fusion by mitofusins; then IMM fusion by OPA1). The two steps are kinetically distinct: OMM fusion can transiently uncouple from IMM fusion, producing “hemifusion” intermediates with connected OMMs but separate matrices. OPA1-mediated IMM fusion requires GTP hydrolysis and is driven by the conformational change in the GTPase domain acting on the curved IMM ²³.

Why both steps are required:

• OMM fusion alone (without IMM fusion) allows OMM continuity but does not permit matrix content mixing (mtDNA, metabolites, soluble proteins). Only complete fusion — OMM + IMM — produces true mitochondrial content mixing.
• Content mixing is the functional purpose of fusion: it dilutes damaged mtDNA variants and redistributes oxidized proteins from damaged mitochondria into the healthy network, maintaining organelle quality across the network.

The net activity of OPA1 (IMM fusion) versus drp1 (IMM/OMM fission) determines the overall IMM and cristae morphology. Fusion-dominant networks produce elongated, interconnected mitochondria with stacked, tight cristae; fission-dominant networks produce small, punctate, round mitochondria with simplified cristae.

Function 2 — Cristae junction control and cytochrome c release gating

OPA1 oligomers assemble at cristae junctions — the narrow, tubular connections (~10–25 nm diameter) between the cristae lumen and the IMS. Under normal conditions, OPA1 oligomers keep cristae junctions tight, confining the bulk of cytochrome c to the cristae interior. This is mechanistically important for apoptosis regulation:

Frezza et al. 2006 report that only ~15–20% of total cytochrome c floats freely in the IMS and is immediately available to cross the OMM when MOMP occurs via BAX/BAK pores; the remaining ~80–85% is stored inside cristae ⁴. BID cleavage by caspase-8 generates tBID, which triggers OPA1 oligomer disassembly, widens cristae junctions, and mobilises the cristae-stored pool, producing a surge in cytosolic cytochrome c that drives robust apoptosome assembly and committed caspase activation ⁴.

Frezza et al. 2006 demonstrated this using a combination of purified mitochondria, immunodepletion, and structural analysis (electron microscopy of cristae junction width):

• OPA1 knockdown or expression of fusion-defective OPA1 point mutants augmented cytochrome c release and accelerated apoptosis upon MOMP induction
• OPA1 overexpression retarded cytochrome c release and delayed caspase activation
• Critically: OPA1’s antiapoptotic function was demonstrated in Mfn1-null MEFs — cells incapable of OMM fusion — establishing that the cristae-junction role is independent of IMM fusion ⁴

This finding, now well-replicated in the field, means OPA1 sits at the intersection of two aging-relevant processes: it gates cytochrome-c availability during apoptosis, and it is required for mitophagy isolation (via OMA1-mediated S-OPA1 conversion halting fusion on damaged mitochondria).

Dimension	Status
Pathway conserved in humans?	yes — mechanism characterised in human cell lines (Mfn1-null MEFs are murine but mechanism conserved)
Phenotype conserved in humans?	yes — cytochrome c release as apoptotic commitment step conserved
Replicated in humans?	partial — original Frezza 2006 is murine + cell-line; human in-vivo data on OPA1/cristae junction in aging lacking needs-human-replication

Disease — Autosomal dominant optic atrophy (ADOA / Kjer’s disease)

OPA1 haploinsufficiency is the cause of ADOA (OMIM 165500), the most common inherited optic neuropathy. Reported prevalence estimates range from 1:12,000 to 1:50,000 ³; Delettre et al. 2000 cite ~1 in 50,000 ². Two groups simultaneously identified OPA1 mutations as causative in 2000:

• Alexander et al. 2000 cloned OPA1 as a novel dynamin-related GTPase mutated at chromosome 3q28 in ADOA families ³.
• Delettre et al. 2000 independently identified OPA1 mutations by positional cloning in ADOA families; they characterised the eight splice isoforms and established differential expression ².

Clinical features of ADOA:

• Progressive bilateral visual loss typically beginning in the first or second decade of life
• Centrocecal scotoma (visual field defect centred on the fixation point and blind spot)
• Optic disc pallor (temporal pallor reflecting retinal ganglion cell (RGC) loss)
• Tritanopia (blue-yellow colour vision defect)
• Autosomal dominant inheritance with variable and incomplete penetrance (Delettre et al. 2000 lod-score calculations use 75%; expressivity varies widely even within families) ²

Haploinsufficiency mechanism: One functional OPA1 allele is insufficient for retinal ganglion cell survival; the threshold effect likely reflects the high energetic demands of RGC axons running the length of the optic nerve. The selective vulnerability of RGCs mirrors the axonal dependence on mitochondrial fusion seen in MFN2/CMT2A.

OPA1-Plus (DOA+): A subset of ADOA families with more severe, multisystem presentations — including sensorineural deafness, myopathy, ataxia, and peripheral neuropathy — map to OPA1 mutations clustered in the GTPase domain. Mechanism: dominant-negative effect (rather than haploinsufficiency) for GTPase-domain mutations.

Additional OPA1-linked phenotypes: Behr syndrome (optic atrophy + spastic paraplegia + cerebellar ataxia); mitochondrial DNA depletion syndrome 14 (rare biallelic null mutations; more severe multisystem).

Mouse knockout and heterozygous phenotypes

• Opa1−/− (homozygous null): Embryonic lethal at approximately E9.5 — among the earliest lethal mitochondrial fusion knockouts, reflecting the absolute requirement for OPA1 during early embryogenesis. needs-replication — precise staging relative to Mfn1−/− and Mfn2−/− lethality should be confirmed.
• Opa1+/− (heterozygous): Viable. Heterozygous mice develop progressive retinal ganglion cell degeneration and optic nerve atrophy, modelling human ADOA. Motor and cognitive phenotypes have also been reported in some genetic backgrounds. This mirrors the haploinsufficiency mechanism in human ADOA.
• Conditional knockouts: Cardiac and skeletal-muscle-specific Opa1 cKO models have been generated and show mitochondrial fragmentation, bioenergetic failure, and cardiomyopathy or myopathy respectively. These models demonstrate that sustained IMM fusion capacity is required for normal post-mitotic tissue homeostasis.

Aging relevance

OPA1 reduction in aged tissues

Multiple lines of evidence document OPA1 protein decline with age, consistent with the broader shift from fusion-dominant to fission-dominant mitochondrial network morphology in aged post-mitotic tissues:

• Skeletal muscle aging: OPA1 mRNA and protein levels decline in aged rodent and human skeletal muscle, correlating with increased mitochondrial fragmentation, reduced respiratory chain function, and impaired mitophagy flux. Whether OPA1 decline is causal or a downstream consequence of energetic stress-induced OMA1 activation is not yet resolved. no-mechanism
• Cardiac aging / heart failure: Cardiac OPA1 protein levels are reduced in failing human hearts and in aged mouse cardiomyocytes, correlating with dysmorphic cristae, reduced Complex I/IV activity, and impaired contractile reserve. OPA1 overexpression in mouse heart failure models has been reported to partially restore cristae morphology and cardiac function, though the mechanism of benefit is not cleanly separated between fusion vs cristae-junction vs cytochrome c effects. needs-replication — Human mechanistic data lacking.

Dimension	Status
Pathway conserved in humans?	yes — OPA1 present and functionally characterised in human tissues
Phenotype conserved in humans?	partial — cardiac OPA1 reduction in HF confirmed in humans; aging-specific OPA1 quantification in humans is limited
Replicated in humans?	no — causal role of OPA1 decline in human tissue aging not established needs-human-replication

Fusion arrest as mitophagy gating mechanism

When ΔΨm collapses on a damaged mitochondrion, OMA1 activation converts L-OPA1 to S-OPA1, fusing OPA1-mediated IMM fusion arrest with PINK1 stabilization-mediated Parkin recruitment. This creates a dual gating system: OMM fusion arrest (via Parkin-mediated MFN1/MFN2 degradation, see mitofusins) and IMM fusion arrest (via OMA1-mediated OPA1 cleavage) together isolate the damaged organelle, ensuring it cannot dilute its dysfunction by re-fusing with the healthy network before mitophagy receptors complete engulfment. Age-associated decline in this OMA1-sensitivity or in basal OPA1 levels may compromise this gating fidelity, contributing to accumulation of poorly eliminated damaged mitochondria.

Cristae morphology and respiratory chain supercomplex stability

IMM cristae morphology, maintained by OPA1 oligomers, is required for the formation and stability of respiratory chain supercomplexes (the “respirasomes”: Complex I–III₂–IV assemblies). Dysmorphic, less tightly packed cristae — as seen with OPA1 loss or oligomer disassembly — impair supercomplex formation, reduce Complex I activity, and increase electron leak (ROS). This mechanistic chain (OPA1 decline → cristae disruption → supercomplex destabilization → reduced OXPHOS efficiency + increased ROS) links the fusion machinery directly to the bioenergetic component of mitochondrial-dysfunction in aging. needs-replication — The quantitative relationship between OPA1 levels and supercomplex abundance in aged human tissue is not established.

Pathway membership

• mitophagy — OMA1-mediated OPA1 cleavage enforces IMM fusion arrest on depolarised mitochondria; prerequisite for effective mitophagy isolation (coordinate with MFN1/MFN2 degradation by Parkin)
• mitochondrial-dynamics — with mitofusins (OMM fusion) and drp1 (fission), constitutes the core mitochondrial fusion-fission machinery; OPA1 is the sole IMM fusion GTPase
• mitochondrial-dysfunction — OPA1 loss or reduction causes the cristae dysmorphia, respiratory chain destabilization, and fragmentation that characterise aged mitochondria

Key interactors

• mitofusins (MFN1/MFN2) — OMM fusion partners; both OMM fusion (by MFN1/MFN2) and IMM fusion (by OPA1) are required sequentially for complete mitochondrial merger; OPA1 oligomers are downstream of MFN-mediated OMM tethering
• cytochrome-c — OPA1 oligomers gate cytochrome c release from cristae; tBID-triggered OPA1 disassembly widens cristae junctions to mobilise the ~80–85% of cytochrome c stored in the cristae (Frezza 2006: ~15–20% is IMS-free at baseline) ⁴
• oma1 — IMM-resident zinc metalloprotease; activated by ΔΨm loss and stress; cleaves L-OPA1 at S1 site → S-OPA1; the primary stress-responsive OPA1 regulatory protease (verified R25 against Ehses 2009 + Baker 2014 PDFs)
• yme1l — i-AAA protease with active site facing the IMS; cleaves OPA1 at S2 site constitutively; counteracts OMA1 under baseline conditions; the YME1L/OMA1 balance determines L-OPA1/S-OPA1 equilibrium (verified R25 against Hartmann 2016 + Stiburek 2012 PDFs)
• drp1 — opposing fission GTPase; OPA1 activity opposes DRP1-driven fission; the OPA1/DRP1 ratio governs cristae morphology and network fragmentation state

Pharmacology

No approved drugs directly target OPA1. Investigational strategies are in preclinical stage:

• OPA1 stabilization / OMA1 inhibition: Preclinical tool compounds that inhibit OMA1 (to prevent stress-induced L-OPA1 depletion) have been studied in ischaemia/reperfusion injury models, with partial protection of cardiac mitochondrial morphology. No clinical candidates as of 2026-05-04. long-term-unknown
• Mitochondria-targeted peptides: SS-31 (elamipretide) targets cardiolipin on the IMM and indirectly stabilises cristae morphology, partially restoring OPA1 oligomer function; currently in clinical trials for heart failure and Barth syndrome (see elamipretide). The degree to which OPA1 stabilization specifically explains SS-31 benefit is unresolved. no-mechanism
• Gene therapy: AAV-mediated OPA1 delivery has been explored in Opa1+/− mouse RGC degeneration models. Clinical gene therapy for ADOA is at very early investigational stage. long-term-unknown

ClinicalTrials.gov: No registered trials targeting OPA1 directly as of 2026-05-04. ADOA management is symptomatic; LHON gene therapy trials (targeting ND4) are not OPA1-directed. needs-canonical-id — ClinicalTrials.gov query should be repeated at next lint pass.

Limitations and gaps

• #gap/needs-human-replication — Quantitative OPA1 protein decline with aging in human cardiac and skeletal muscle is reported but the mechanistic contribution to functional decline (vs. downstream of energetic failure → OMA1 activation) is not established causally in humans.
• #gap/needs-replication — Whether restoring OPA1 levels or oligomerisation in aged animal models extends healthspan or corrects mitophagy flux deficits in a reproducible, multi-laboratory context has not been shown.
• #gap/no-mechanism — The conformational mechanism by which OPA1 oligomers seal cristae junctions at the structural level (oligomer stoichiometry, membrane-bending geometry) is not fully resolved; cryo-tomography data are emerging but incomplete.
• #gap/long-term-unknown — Pharmacological OPA1 stabilization or OMA1 inhibition has been tested only in acute stress (ischaemia/reperfusion) models, not in chronic aging contexts or long-term longevity studies.
• OPA1 is absent from GenAge-human as of 2026-05-04 — no formal aging-gene classification, despite clear mechanistic involvement in aging-relevant mitochondrial quality control.

Footnotes

Footnotes

1. doi:10.1083/jcb.201308006 · n=N/A · in-vitro (mouse MEFs + HeLa) · mechanism · model: YME1L and OMA1 double-knockout MEFs; cleavage-site mutants; established that YME1L (S2, constitutive) and OMA1 (S1, stress-induced) together balance L-OPA1/S-OPA1 equilibrium; OMA1 activation by ΔΨm collapse responsible for rapid conversion of all L-OPA1 to S-OPA1 · 755 citations (archive confirmed; not OA; no local PDF — claims independently confirmed via Hartmann 2016 + Ehses 2009 + Baker 2014 PDFs in R25 verification pass) ↩

2. doi:10.1038/79936 · n=N/A · observational (human genetics; positional cloning) · model: ADOA families; cloned OPA1 independently; first description of 8 splice isoforms (alternative exons 4, 4b, 5b); characterised differential tissue expression · 1,412 citations (archive confirmed; local PDF at ) ↩ ↩² ↩³ ↩⁴

3. doi:10.1038/79944 · n=N/A · observational (human genetics + expression cloning) · model: ADOA families linked to 3q28; identified OPA1 as a dynamin-related GTPase gene mutated in affected individuals; characterised expression pattern and subcellular localisation · 1,302 citations (archive confirmed; local PDF at ) ↩ ↩² ↩³

4. doi:10.1016/j.cell.2006.06.025 · n=N/A · in-vitro (mouse Mfn1-null MEFs + additional mouse MEF lines) · mechanism · model: OPA1 siRNA knockdown and overexpression; BID-induced cytochrome c release assayed by fluorescence + immunogold EM; established that OPA1 oligomers seal cristae junctions and that OPA1 disassembly by tBID widens junctions to release ~85% cristae-stored cytochrome c; separation of IMM fusion function from cristae-junction function demonstrated in fusion-incompetent Mfn1-null MEFs · 1,616 citations (archive confirmed; OA bronze; local PDF at ) — verified on cytochrome-c (2026-05-04); core quantitative and mechanistic claims confirmed ↩ ↩² ↩³ ↩⁴